Konruns(SH:603590) Xin Lang Cai Jing·2025-10-15 14:29Core Viewpoint - Kangchen Pharmaceutical plans to repurchase shares through centralized bidding, with a total amount between 50 million and 100 million yuan, and a maximum repurchase price of 82.00 yuan per share, which is 66.97% higher than the current price of 49.11 yuan [1] Group 1: Company Overview - Kangchen Pharmaceutical, established on September 3, 2003, and listed on August 27, 2018, is located in Changping District, Beijing, and focuses on innovative drug research and development [1] - The company's main business revenue composition includes Suling (70.77%), Salmon Calcitonin (29.15%), and others (0.09%) [1] - The company operates in the pharmaceutical and biotechnology sector, specifically in the bioproducts category [1] Group 2: Financial Performance - As of June 30, 2025, Kangchen Pharmaceutical achieved operating revenue of 461 million yuan, a year-on-year increase of 13.79%, and a net profit attributable to shareholders of 91.05 million yuan, up 14.95% year-on-year [2] - The company has distributed a total of 437 million yuan in dividends since its A-share listing, with 175 million yuan distributed over the past three years [3] Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 10.82% to 9,970, while the average circulating shares per person increased by 12.14% to 15,771 shares [2] - Notable institutional shareholders include Penghua Medical Technology Stock A, E Fund Healthcare Industry Mixed A, and CITIC Jianxin Medical Reform A, with varying increases in holdings [3]